• This is Vicore
    • Our story
    • Our ambition and strategic priorities
    • Our team
    • Collaborations and partnerships
    • Our collaborative business model
    • Scientific advisors
    • Management team
    • Board of Directors
  • ATRAGs
    • ATRAG MoA in IPF
    • Scientific rationale
    • Our drug discovery engine
    • Intellectual property and orphan drug designation
    • Publications
      • Key publications
      • Posters
  • Our programs
    • Pipeline
    • Rare lung diseases
      • C21 – IPF fibrosis
      • Almee – PF anxiety
      • Thalidomide – IPF cough
      • PAH
    • Future ATRAG indications
  • Almee™
  • Career
    • Our collaborative business model
    • Open positions
    • Contact
    • Our Team (interviews)
  • Media
    • Press releases
    • Pressmeddelanden
    • Image bank
  • Investors
    • Investors
      • Overview
      • Press releases
      • Our equity story
      • The share
      • Company presentation
      • Financial reports
      • Financial calendar
      • Events & Presentations
      • Corporate governance
      • Corporate governance reports
      • Image bank
      • Investor Relations contact
    • Investerare (SE)
      • Översikt
      • Pressmeddelanden
      • Översikt
      • Aktien
      • Finansiella rapporter
      • Finansiell kalender
      • Events & Presentationer
      • Bolagsstyrning
      • Bolagsstyrningsrapporter
      • Prenumerera på nyheter
      • Bildbank
      • Investerarkontakt
  • Patients and caregivers
    • IPF
      • Patient stories
      • Patient advocacy organizations
    • Transparency
    • PAH
      • Patient stories
      • Patient advocacy organizations
    • The patient perspective in clinical trials
    • Access policy
    • Working with patient groups
logo
  • This is Vicore
    • Our story
    • Our ambition and strategic priorities
    • Collaborations and partnerships
    • Scientific advisors
    • Management team
    • Board of Directors
  • Science
    • Scientific rationale
    • ATRAG MoA in IPF
    • Intellectual property and orphan drug designation
    • Publications
      • Key publications
      • Posters
  • Our programs
    • Pipeline
    • Rare lung diseases
      • C21 – IPF fibrosis
      • Almee – PF anxiety
      • Thalidomide – IPF cough
      • C21 – PAH
    • Future ATRAG indications
    • Our drug discovery engine
Almee™
  • Career
    • Our collaborative business model
    • Meet the Team
    • Open positions
    • Contact
  • Media
    • Press releases (ENG)
    • Pressmeddelanden (SVE)
    • Image bank
  • Investors
    • Investors
      • Overview
      • Press releases
      • The share
      • Financial reports
      • Financial calendar
      • Events & Presentations
      • Corporate governance
      • Image bank
      • Investor Relations contact
    • Investerare (SE)
      • Översikt
      • Pressmeddelanden
      • Aktien
      • Finansiella rapporter
      • Finansiell kalender
      • Events & Presentationer
      • Bolagsstyrning
      • Bolagsstämma
      • Bildbank
      • Investerarkontakt
  • Patients and caregivers
    • IPF
      • Background
      • Patient stories
      • Patient advocacy organizations
    • Transparency
    • Access policy
logo
Home / Investors / Press releases / Press
logo
Vicore Pharma’s offices

Kornhamnstorg 53
SE-111 27 Stockholm, Sweden

Agern Allé 5A
DK-2970 Hørsholm, Denmark

Cambridge Innovation Center
14th floor, One Broadway, Cambridge
MA 02142, USA

We'd love to hear from you!
Phone: +46 (0) 31 788 05 60 Mail: info@vicorepharma.com
Billing and mailing address:

Vicore Pharma
Postbox 14
414 51 Gothenburg, Sweden

Quick links
Contact Subscribe to press releases Privacy Policy Cookies